603739.SH announced that Shandong Azure Biotechnology Co., Ltd., a wholly owned subsidiary of the company, and Yingchuang (China) Investment Co., Ltd. signed a shareholder Agreement on October 12, 2023. The two sides plan to jointly establish a Sino-foreign joint venture company (hereinafter referred to as the "joint venture company") in Huimin County, Binzhou City, Shandong Province, China. Shandong Weilan Biotechnology Co., Ltd. will be entrusted by the joint venture company to produce GHS products exclusively for the joint venture company. Shandong Ulan and Yingchuang China will inject business related to GHS products into the joint venture in accordance with the shareholders Agreement. Shandong Ulan has the right to receive the benefits agreed in the shareholder Agreement from the joint venture.
The registered capital of the joint venture company is RMB 37.5 million, of which Shandong Ulan subscribed investors RMB 16.875 million, accounting for 45%, winning China's subscription of RMB 20.625 million, accounting for 55%. The total investment of the joint venture company is 80 million yuan.